Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?

Amgen stock popped Monday after its experimental drug showed promise in hard-to-treat lung and colon cancers.

The biotech is working to treat cancer by blocking a mutated protein called KRAS. Amgen tested its cancer treatment, called AMG 510, in patients who previously worsened while undergoing at least two rounds of prior therapy.